DONALD YEE to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications DONALD YEE has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.254
-
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27; 9(10):2461-2472.
Score: 0.134
-
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv. 2023 10 24; 7(20):6055-6065.
Score: 0.120